Braveheart Bio, Inc. (BRVE) stock
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.53−0.25 (-1.33%)
Close on Nov 18, 2026Market cap $1.67BP/E –Yield –
Braveheart Bio net income
Net income is the profit left for shareholders after every expense, interest and tax.
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$26.50M | – |
| Q2 FY2026 | Jun 30, 2026 | -$14.99M | – |
| Q1 FY2026 | Mar 31, 2026 | -$14.28M | – |
| Q3 FY2025 | Sep 30, 2025 | -$59.12M | – |
| Q2 FY2025 | Jun 30, 2025 | -$381.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$99.00K | – |
See a number that looks wrong?